Caixia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Caixia Wang has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Baorui Lin
Tianjin University
1 shared publication- Chengwu Zeng
Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China
1 shared publication - Chunlei Li
Shandong Provincial Key Laboratory for Bio-Manufacturing, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China
1 shared publication - Cunte Chen
Guangzhou First People's Hospital, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510700, China
1 shared publication Daohao Tang
School of Pharmaceutical Sciences, Jilin University, Changchun 130021, PR China
1 shared publication- Fang Xu
Henan Normal University
1 shared publication
Latest Publications
- 21 January 2024
- Published by Elsevier in Phytomedicine
- Vol. 128, 155366
Novel applications of Yinhua Miyanling tablets in ulcerative colitis treatment based on metabolomics and network pharmacology
- 21 January 2024
- Published by Elsevier in Phytomedicine
- Vol. 128, 155366
Novel applications of Yinhua Miyanling tablets in ulcerative colitis treatment based on metabolomics and network pharmacology
- Open Access
- 22 September 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (12) , 4748-4764
Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma
- 22 September 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (12) , 4748-4764
Open AccessPreclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma
- Open Access
- 1 February 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
Positive response to PD-1/PD-L1 blockades was observed in the treatment of solid tumors. However, the clinical response to PD-1/PD-L1 blockade varied in patients with acute myeloid leukemia (AML). It is thought that there are factors other than PD-1 and PD-L1 that may affect the effect of immunotherapy. This study explored the impact of transcriptome-based co-expression of bromodomain containing 4 (BRD4) and PD-1/PD-L1 on the overall survival (OS) of patients with AML, in order to understand whether BRD4 would affect the effect of PD-1/PD-L1 blockades. Bone marrow samples from 59 AML patients in our clinical center and data of 176 patients from the Cancer Genome Atlas (TCGA) database were used for OS analysis and validation. It was found that increased expression of BRD4 was associated with poor OS in AML patients. Moreover, co-expression of BRD4 with PD-1 or PD-L1 was related to poor OS. The co-expression of BRD4 and PD-L1 was better than BRD4 and PD-1 for OS prediction. Furthermore, co-expression of BRD4 and PD-L1 was positively correlated with high tumor mutation burden, which contributed to poor OS in AML patients. Additionally, the co-expression of BRD4 and PD-L1 was associated with poor OS in non-acute promyelocytic leukemia patients with intermediate/high risk or under 60 years. Our results suggest that transcriptome-based co-expression of BRD4 and PD-L1 is a predictor for poor OS in AML patients, which might provide novel insight into designing combinational targeted therapy for AML.
- 1 February 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Open AccessTranscriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
Positive response to PD-1/PD-L1 blockades was observed in the treatment of solid tumors. However, the clinical response to PD-1/PD-L1 blockade varied in patients with acute myeloid leukemia (AML). It is thought that there are factors other than PD-1 and PD-L1 that may affect the effect of immunotherapy. This study explored the impact of transcriptome-based co-expression of bromodomain containing 4 (BRD4) and PD-1/PD-L1 on the overall survival (OS) of patients with AML, in order to understand whether BRD4 would affect the effect of PD-1/PD-L1 blockades. Bone marrow samples from 59 AML patients in our clinical center and data of 176 patients from the Cancer Genome Atlas (TCGA) database were used for OS analysis and validation. It was found that increased expression of BRD4 was associated with poor OS in AML patients. Moreover, co-expression of BRD4 with PD-1 or PD-L1 was related to poor OS. The co-expression of BRD4 and PD-L1 was better than BRD4 and PD-1 for OS prediction. Furthermore, co-expression of BRD4 and PD-L1 was positively correlated with high tumor mutation burden, which contributed to poor OS in AML patients. Additionally, the co-expression of BRD4 and PD-L1 was associated with poor OS in non-acute promyelocytic leukemia patients with intermediate/high risk or under 60 years. Our results suggest that transcriptome-based co-expression of BRD4 and PD-L1 is a predictor for poor OS in AML patients, which might provide novel insight into designing combinational targeted therapy for AML.
- 3 August 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 399 (1-2) , 31-36
Nigericin-mediated liposome loading of topotecan: Is nigericin a potential drug release regulator?
- 3 August 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 399 (1-2) , 31-36
Nigericin-mediated liposome loading of topotecan: Is nigericin a potential drug release regulator?
- 1 December 2006
- Published by Pleiades Publishing Ltd in Colloid Journal
- Vol. 68 (6) , 779-783
Methoxy poly(ethylene glycol)-conjugated linoleic acid polymeric micelles for paclitaxel delivery
A methoxy poly(ethylene glycol) (MePEG)-conjugated linoleic acid (CLA) polymeric conjugate is synthesized with the use of dicyclohexycarbodiimide and 4-dimethylaminopyridine as the coupling agent and the catalyst, respectively. Self-assembled MePEG-CLA conjugate micelles are prepared by dialysis in water. Fluorescence spectroscopy indicates that the MePEG-CLA conjugate exhibits a typical core-shell micellar structure, and the estimated critical micelle concentration is 1.2 × 10−5 mol L−1. Dynamic light scattering and transmission electron microscopy demonstrate that the prepared MePEG-CLA micelles have spherical shape and an average diameter of approximately 100 nm. Paclitaxel is entrapped into MePEG-CLA lyophilized powder. The release of paclitaxel from the loaded micelles is investigated in vitro. A biphasic release pattern with a fast release rate followed by a slow release is observed.
- 1 December 2006
- Published by Pleiades Publishing Ltd in Colloid Journal
- Vol. 68 (6) , 779-783
Methoxy poly(ethylene glycol)-conjugated linoleic acid polymeric micelles for paclitaxel delivery
A methoxy poly(ethylene glycol) (MePEG)-conjugated linoleic acid (CLA) polymeric conjugate is synthesized with the use of dicyclohexycarbodiimide and 4-dimethylaminopyridine as the coupling agent and the catalyst, respectively. Self-assembled MePEG-CLA conjugate micelles are prepared by dialysis in water. Fluorescence spectroscopy indicates that the MePEG-CLA conjugate exhibits a typical core-shell micellar structure, and the estimated critical micelle concentration is 1.2 × 10−5 mol L−1. Dynamic light scattering and transmission electron microscopy demonstrate that the prepared MePEG-CLA micelles have spherical shape and an average diameter of approximately 100 nm. Paclitaxel is entrapped into MePEG-CLA lyophilized powder. The release of paclitaxel from the loaded micelles is investigated in vitro. A biphasic release pattern with a fast release rate followed by a slow release is observed.
- 6 December 2005
- Published by IOP Publishing in Superconductor Science and Technology
- Vol. 19 (1) , 122-128
Superconductivity and magnetism in the mixed-valence Mn doped La1.85−1.5xSr0.15+1.5xCu1−xMnxO4 system
- 6 December 2005
- Published by IOP Publishing in Superconductor Science and Technology
- Vol. 19 (1) , 122-128
Superconductivity and magnetism in the mixed-valence Mn doped La1.85−1.5xSr0.15+1.5xCu1−xMnxO4 system